Investment analysts at Evercore ISI started coverage on shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in a research note issued to investors on Wednesday. The brokerage set an “outperform” rating and a $605.00 price target on the biopharmaceutical company’s stock. Evercore ISI’s target price would suggest a potential upside of 29.12% from the company’s current price.

A number of other equities analysts also recently commented on REGN. Vetr downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $408.86 price objective on the stock. in a research report on Monday, April 24th. Zacks Investment Research upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $416.00 price objective on the stock in a research report on Thursday, April 27th. BMO Capital Markets reiterated a “hold” rating and set a $421.00 price objective (up previously from $412.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, May 5th. Cowen and Company reiterated a “hold” rating and set a $380.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Friday, May 5th. Finally, Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Thursday, May 4th. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $495.59.

Shares of Regeneron Pharmaceuticals (NASDAQ REGN) opened at 468.54 on Wednesday. The stock has a market capitalization of $49.68 billion, a PE ratio of 47.00 and a beta of 1.66. Regeneron Pharmaceuticals has a one year low of $325.35 and a one year high of $543.55. The stock’s 50 day moving average price is $492.11 and its 200 day moving average price is $429.80.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, topping the Zacks’ consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The firm had revenue of $1.47 billion for the quarter, compared to the consensus estimate of $1.36 billion. During the same quarter last year, the business posted $2.82 earnings per share. The firm’s revenue was up 21.2% compared to the same quarter last year. Equities research analysts predict that Regeneron Pharmaceuticals will post $14.84 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/16/regeneron-pharmaceuticals-inc-regn-research-coverage-started-at-evercore-isi.html.

In other Regeneron Pharmaceuticals news, EVP Neil Stahl sold 8,306 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $532.55, for a total transaction of $4,423,360.30. Following the completion of the sale, the executive vice president now directly owns 43,950 shares of the company’s stock, valued at approximately $23,405,572.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman P Roy Vagelos sold 9,295 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $458.14, for a total value of $4,258,411.30. Following the sale, the chairman now directly owns 414,156 shares of the company’s stock, valued at $189,741,429.84. The disclosure for this sale can be found here. Insiders have sold a total of 56,922 shares of company stock valued at $27,383,105 over the last three months. 10.40% of the stock is currently owned by insiders.

A number of hedge funds have recently made changes to their positions in the company. BlackRock Inc. increased its stake in shares of Regeneron Pharmaceuticals by 3,331.5% in the first quarter. BlackRock Inc. now owns 6,146,861 shares of the biopharmaceutical company’s stock worth $2,381,971,000 after buying an additional 5,967,733 shares during the period. Janus Henderson Group PLC increased its stake in shares of Regeneron Pharmaceuticals by 15,495.4% in the second quarter. Janus Henderson Group PLC now owns 1,562,970 shares of the biopharmaceutical company’s stock worth $767,637,000 after buying an additional 1,552,948 shares during the period. Jennison Associates LLC increased its stake in shares of Regeneron Pharmaceuticals by 74.1% in the second quarter. Jennison Associates LLC now owns 1,292,863 shares of the biopharmaceutical company’s stock worth $634,977,000 after buying an additional 550,247 shares during the period. Janus Capital Management LLC increased its stake in shares of Regeneron Pharmaceuticals by 58.5% in the first quarter. Janus Capital Management LLC now owns 1,317,162 shares of the biopharmaceutical company’s stock worth $510,406,000 after buying an additional 486,119 shares during the period. Finally, Wellington Management Group LLP increased its stake in shares of Regeneron Pharmaceuticals by 7.9% in the first quarter. Wellington Management Group LLP now owns 6,135,559 shares of the biopharmaceutical company’s stock worth $2,377,590,000 after buying an additional 446,850 shares during the period. 67.16% of the stock is owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.